Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naïve Follicular Lymphoma

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2, open label study to assess umbralisib in combination with ublituximab in subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TG Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Confirmed diagnosis of Follicular Lymphoma (FL) or Small Lymphocytic Lymphoma (SLL).

• Measurable disease that requires treatment

• ECOG performance status ≤ 1

Exclusion Criteria:

• Currently or previously received treatment for their lymphoma

• Received wide field radiotherapy within 28 days or limited field radiation within 14 days of Cycle 1 Day 1

• Evidence of hepatitis B virus, hepatitis C virus or known HIV infection